Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Scale up of reagent production for the use in rapid diagnostics

Reference number
Coordinator Readily AB
Funding from Vinnova SEK 1 000 000
Project duration November 2024 - October 2025
Status Completed
Venture Utlysning Infrastruktur for the development of accurate drug treatment
Call Use infrastructures to develop precision medicine

Important results from the project

Our objective for the project was to learn more about production processes and verification processes when it comes to some of our key reagents. We have learned processes around scale-up and verification. This project has been very relevant and useful for our company and we will now be able to confidently start production of these reagents. In the long term, it will give us the opportunity to offer diagnostics to healthcare at a lower cost.

Expected long term effects

Being able to produce these reagents and verify them within our own company not only allows us to offer our end product at a lower cost - it also makes us less vulnerable to external influences that affect deliveries and finances. We want to be independent and control our processes. This project has enabled us to take a big step forward in this process.

Approach and implementation

The project was implemented by having meetings between our employees - project managers and infrastructure employees. There we went through our plans and objective for the project. Together, a timetable was made for implementation. Our employees were on site for two periods of three weeks where they learned the processes and production. At the end of the project, a summary report was written on what had been done and where we could summarize that our objective had been achieved.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 5 December 2025

Reference number 2024-02544